Literature DB >> 22183444

Expression of RECK in endothelial cells of glioma: comparison with CD34 and VEGF expressions.

Nunung Nur Rahmah1, Keiichi Sakai, Kenji Sano, Kazuhiro Hongo.   

Abstract

Angiogenesis is thought to be involved in the progression of glioma grades, and reversion-inducing cysteine-rich protein with Kazal motifs (RECK) has been said to be involved in maturation of vessels. In this study, we aimed to determine whether high micro-vessel density (MVD) expressed by RECK in glioma tissue is correlated with grades of glioma. We also compared RECK expression with that of the formerly known vessel marker, CD34, and vascular endothelial growth factor (VEGF). RECK, CD34, and VEGF immuno-reactivities of 72 glioma tissues were studied. RECK was seen in microvessels of glioma tissues. CD34 showed a similar pattern to RECK, whereas VEGF showed positive staining in cytoplasm of tumor cells and endothelial cells. Average MVD with RECK was 107.6 microvessels (range 7-290). RECK was positively correlated with grades of glioma. RECK and CD34 also showed a strong correlation (P = 0.001). Higher frequency of VEGF staining was also correlated with higher grade of glioma. This is the first study describing expression of RECK in glioma, and its angiogenesis-related nature may provide a potential therapeutic target for glioma treatment in the future.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22183444     DOI: 10.1007/s11060-011-0778-z

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  27 in total

1.  The role of the vascular phase in solid tumor growth: a historical review.

Authors:  D Ribatti; A Vacca; F Dammacco
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

2.  The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis.

Authors:  J Oh; R Takahashi; S Kondo; A Mizoguchi; E Adachi; R M Sasahara; S Nishimura; Y Imamura; H Kitayama; D B Alexander; C Ide; T P Horan; T Arakawa; H Yoshida; S Nishikawa; Y Itoh; M Seiki; S Itohara; C Takahashi; M Noda
Journal:  Cell       Date:  2001-12-14       Impact factor: 41.582

3.  Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance.

Authors:  M Maxwell; S P Naber; H J Wolfe; T Galanopoulos; E T Hedley-Whyte; P M Black; H N Antoniades
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

4.  The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) interacts with membrane type 1 matrix metalloproteinase and CD13/aminopeptidase N and modulates their endocytic pathways.

Authors:  Takao Miki; Yujiro Takegami; Katsuya Okawa; Teruyuki Muraguchi; Makoto Noda; Chiaki Takahashi
Journal:  J Biol Chem       Date:  2007-02-28       Impact factor: 5.157

Review 5.  RECK--a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer.

Authors:  Jonathan C M Clark; David M Thomas; Peter F M Choong; Crispin R Dass
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

Review 6.  Recklessness as a hallmark of aggressive cancer.

Authors:  Makoto Noda; Chiaki Takahashi
Journal:  Cancer Sci       Date:  2007-08-28       Impact factor: 6.716

7.  Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK.

Authors:  C Takahashi; Z Sheng; T P Horan; H Kitayama; M Maki; K Hitomi; Y Kitaura; S Takai; R M Sasahara; A Horimoto; Y Ikawa; B J Ratzkin; T Arakawa; M Noda
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

8.  The potential role of basic fibroblast growth factor in the transformation of cultured primary human fetal astrocytes and the proliferation of human glioma (U-87) cells.

Authors:  S Gately; G A Soff; S Brem
Journal:  Neurosurgery       Date:  1995-10       Impact factor: 4.654

9.  Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas.

Authors:  Gabriel Corteze Netto; Cristina Birlem Bleil; Arlete Hilbig; Lígia Maria Barbosa Coutinho
Journal:  Neuropathology       Date:  2008-02       Impact factor: 1.906

10.  Involvement of the Reck tumor suppressor protein in maternal and embryonic vascular remodeling in mice.

Authors:  Ediriweera P S Chandana; Yasuhiro Maeda; Akihiko Ueda; Hiroshi Kiyonari; Naoko Oshima; Mako Yamamoto; Shunya Kondo; Junseo Oh; Rei Takahashi; Yoko Yoshida; Satoshi Kawashima; David B Alexander; Hitoshi Kitayama; Chiaki Takahashi; Yasuhiko Tabata; Tomoko Matsuzaki; Makoto Noda
Journal:  BMC Dev Biol       Date:  2010-08-06       Impact factor: 1.978

View more
  11 in total

1.  Reck enables cerebrovascular development by promoting canonical Wnt signaling.

Authors:  Florian Ulrich; Jorge Carretero-Ortega; Javier Menéndez; Carlos Narvaez; Belinda Sun; Eva Lancaster; Valerie Pershad; Sean Trzaska; Evelyn Véliz; Makoto Kamei; Andrew Prendergast; Kameha R Kidd; Kenna M Shaw; Daniel A Castranova; Van N Pham; Brigid D Lo; Benjamin L Martin; David W Raible; Brant M Weinstein; Jesús Torres-Vázquez
Journal:  Development       Date:  2015-12-10       Impact factor: 6.868

2.  The overexpression of epithelial cell adhesion molecule (EpCAM) in glioma.

Authors:  Xin Chen; Wei-Yuan Ma; Shang-Chen Xu; Yu Liang; Yi-Bing Fu; Bo Pang; Tao Xin; Hai-Tao Fan; Rui Zhang; Jian-Gang Luo; Wen-Qing Kang; Min Wang; Qi Pang
Journal:  J Neurooncol       Date:  2014-06-07       Impact factor: 4.130

3.  Promoter hypermethylation of the RECK gene is associated with its low expression and poor survival of esophageal squamous cell carcinoma.

Authors:  Jing Zhu; Yang Ling; Yun Xu; Mingzhu Lu; Yongping Liu; Changsong Zhang
Journal:  Oncol Lett       Date:  2017-01-27       Impact factor: 2.967

Review 4.  Looking Inside the Matrix: Perineuronal Nets in Plasticity, Maladaptive Plasticity and Neurological Disorders.

Authors:  Ciro De Luca; Michele Papa
Journal:  Neurochem Res       Date:  2016-03-02       Impact factor: 3.996

5.  TROP2 expression and its correlation with tumor proliferation and angiogenesis in human gliomas.

Authors:  Shanglei Ning; Nan Liang; Bin Liu; Xin Chen; Qi Pang; Tao Xin
Journal:  Neurol Sci       Date:  2013-02-09       Impact factor: 3.307

6.  Interferon-stimulated gene 15 (ISG15) is a trigger for tumorigenesis and metastasis of hepatocellular carcinoma.

Authors:  Chong Li; Ji Wang; Hong Zhang; Mingao Zhu; Feifei Chen; Yufeng Hu; Hudan Liu; Hong Zhu
Journal:  Oncotarget       Date:  2014-09-30

7.  Angiogenesis in human brain tumors: screening of drug response through a patient-specific cell platform for personalized therapy.

Authors:  Laura Guarnaccia; Stefania Elena Navone; Elena Trombetta; Chiara Cordiglieri; Alessandro Cherubini; Francesco Maria Crisà; Paolo Rampini; Monica Miozzo; Laura Fontana; Manuela Caroli; Marco Locatelli; Laura Riboni; Rolando Campanella; Giovanni Marfia
Journal:  Sci Rep       Date:  2018-06-08       Impact factor: 4.379

8.  Down-regulated microRNA-30b-3p inhibits proliferation, invasion and migration of glioma cells via inactivation of the AKT signaling pathway by up-regulating RECK.

Authors:  Yan Jian; Chun-Hua Xu; You-Ping Li; Bin Tang; She-Hao Xie; Er-Ming Zeng
Journal:  Biosci Rep       Date:  2019-08-13       Impact factor: 3.840

9.  Vascular endothelial growth factor participates in modulating the C6 glioma-induced migration of rat bone marrow-derived mesenchymal stem cells and upregulates their vascular cell adhesion molecule-1 expression.

Authors:  Zhiqiang Gao; Peng Cheng; Yixue Xue; Yunhui Liu
Journal:  Exp Ther Med       Date:  2012-09-14       Impact factor: 2.447

Review 10.  CD34 Over-Expression is Associated With Gliomas' Higher WHO Grade.

Authors:  Xiangyi Kong; Jian Guan; Wenbin Ma; Yongning Li; Bing Xing; Yi Yang; Yu Wang; Jun Gao; Junji Wei; Yong Yao; Zhiqin Xu; Wanchen Dou; Wei Lian; Changbao Su; Zuyuan Ren; Renzhi Wang
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.